ardia / Rapid / 0-2.2
elevated hepatic enzymes / Delayed / 0-2.0
hyperbilirubinemia / Delayed / 0-2.0
phlebitis / Rapid / 0-2.0
ST-T wave changes / Rapid / 0-2.0
peripheral edema / Delayed / 0-2.0
palpitations / Early / 0-2.0
edema / Delayed / 0-2.0
orthostatic hypotension / Delayed / 0-2.0
chest pain (unspecified) / Early / 0-2.0
bundle-branch block / Early / 0-2.0
ataxia / Delayed / 0-2.0
constipation / Delayed / 0-2.0
dysuria / Early / 0-2.0
photophobia / Early / 0-2.0
hematuria / Delayed / 0-2.0
hematoma / Early / 0-2.0
anemia / Delayed / 0-2.0
prolonged bleeding time / Delayed / 0-2.0
thrombocytopenia / Delayed / 0-2.0
confusion / Early / 0-2.0
dyspnea / Early / 0-2.0
PR prolongation / Rapid / Incidence not known
QT prolongation / Rapid / Incidence not know
Mild
headache / Early / 7.0-22.9
fatigue / Early / 2.6-5.7
dizziness / Early / 1.3-5.5
diarrhea / Early / 2.1-5.3
fever / Early / 3.5-3.5
dyspepsia / Early / 0-3.0
shivering / Rapid / 0-2.2
chills / Rapid / 0-2.2
injection site reaction / Rapid / 0-2.0
rash (unspecified) / Early / 0-2.0
hyperhidrosis / Delayed / 0-2.0
syncope / Early / 0-2.0
flushing / Rapid / 0-2.0
paresthesias / Delayed / 0-2.0
vertigo / Early / 0-2.0
tremor / Early / 0-2.0
abdominal pain / Early / 0-2.0
anorexia / Delayed / 0-2.0
polyuria / Early / 0-2.0
dysgeusia / Early / 0-2.0
tinnitus / Delayed / 0-2.0
epistaxis / Delayed / 0-2.0
purpura / Delayed / 0-2.0
anxiety / Delayed / 0-2.0
agitation / Early / 0-2.0
urticaria / Rapid / 0-2.0
myalgia / Early / 0-2.0
arthralgia / Delayed / 0-2.0
DRUG INTERACTIONS
Abarelix: Dolasetron has been associated with a dose-dependant prolongation in the QT, PR, and QRS intervals on an electrocardiogram. Dolasetron injection is contraindicated for use for the prevention of chemotherapy-induced nausea and vomiting because the risk of QT prolongation is higher with the doses used for this indication; when the injection is used at lower doses (i.e., those approved for post-operative nausea and vomiting) or when the oral formulation is used, the risk of QT prolongation is lower and caution is advised. Abarelix has a possible risk for QT prolongation and TdP based on varying levels of documentation and should be used with caution with dolasetron.
Acetaminophen; Oxycodone: Serotonin syndrome can occur during concomitant use of opiate agonists with serotonergic drugs, such as serotonin-receptor antagonists. Symptoms may occur hours to days after concomitant use, particularly after dose increases. Serotonin syndrome may occur within recommended dose ranges. If concomitant treatment is clinically warranted, careful observation of the patient is advised, especially during initiation of the second therapy and after dosage increases of either agent. Instruct patients to immediately report symptoms of agitation, hallucinations, tachycardia, fever, excessive sweating, shivering or shaking, muscle twitching or stiffness, trouble with coordination, nausea, vomiting, or diarrhea.
Acetaminophen; Tramadol: Because of the potential risk and severity of serotonin syndrome, use caution when administering dolasetron with other drugs that have serotonergic properties such as tramadol. If serotonin syndrome is suspected, discontinue dolasetron and concurrent serotonergic agents and initiate appropriate medical treatment. Serotonin syndrome is characterized by rapid development of hyperthermia, hypertension, myoclonus, rigidity, a |
